

European Society of Cardiology 2024 Congress

Highlights and key takeaways

August 30 – September 2, 2024





The European Society of Cardiology Congress took place in London between August 30 – September 2, 2024.

Experts from around the globe gathered to share new cutting-edge research and practice-enhancing science in cardiology.

Discussions focused on personalized cardiovascular care was specifically interesting and inspiring to our colleague, Priya Narayan, Managing Consultant and self-proclaimed cardiovascular science enthusiast who was able to meet new colleagues and experts during the congress. The following are her key takeaways.



Key Takeaways

Cardiology is no longer focused on population-based disease

- Rare and congenital diseases are taking centre stage in terms of development and treatment. Congenital diseases and cardiomyopathies like obstructive and non-obstructive HCM, amyloidosis CM were in the spotlight

Cardiovascular disease is increasingly a multi-vector condition and is now being referred to as cardio-renal-metabolic syndrome

- This trifecta is becoming the focus for new treatments
- Landmark data from CVM agents were presented at the meeting that have significant implications in diseases with unmet need like HF w LVEF \geq 40%

Well-served areas like atrial fibrillation, acute coronary syndromes and primary prevention continue to be actively investigated for newer, safer, and cleaner treatment targets across small molecules and biologics

Despite the advances and robust guidelines across the multitude of CV conditions, which are backed with strong long-term evidence- clinical inertia and clinical implementation remain a fundamental problem

Digital diagnostics and treatments are making big waves

- A dedicated fully attended session during the congress suggesting randomized and outcomes-based trials